Ryali Sriram's most recent trade in Caribou Biosciences Inc was a trade of 17,360 Common Stock done at an average price of $1.4 . Disclosure was reported to the exchange on Jan. 29, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Caribou Biosciences Inc | Sriram Ryali | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.42 per share. | 29 Jan 2025 | 17,360 | 17,360 | - | 1.4 | 24,651 | Common Stock |
| Caribou Biosciences Inc | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Jan 2025 | 300,000 | 300,000 | - | - | Option to purchase Common Stock | |
| Codexis Inc. | Ryali Sriram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 314,125 | 314,125 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc. | Ryali Sriram | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2024 | 52,350 | 175,791 (0%) | 0% | 0 | Common Stock | |
| Codexis Inc. | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 372,637 | 372,637 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc. | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2023 | 111,791 | 111,791 (0%) | 0% | 0 | Common Stock | |
| Eiger BioPharmaceuticals Inc | Sriram Ryali | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 5.60 per share. | 14 Mar 2022 | 2,266 | 41,566 (0%) | 0% | 5.6 | 12,683 | Common Stock |
| Eiger BioPharmaceuticals Inc | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jul 2021 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 May 2021 | 87,000 | 87,000 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 97,500 | 97,500 | - | - | Stock Option (Right to Buy) | |
| Eiger BioPharmaceuticals Inc | Sriram Ryali | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Mar 2021 | 16,250 | 18,152 (0%) | 0% | 0 | Common Stock |